4//SEC Filing
Francis Chris 4
Accession 0001193125-26-005195
CIK 0001631574other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 9:30 PM ET
Size
11.0 KB
Accession
0001193125-26-005195
Insider Transaction Report
Form 4
Francis Chris
See Remarks
Transactions
- Exercise/Conversion
Ordinary Shares
2026-01-02$3.14/sh+9,375$29,438→ 34,375 total - Sale
Ordinary Shares
2026-01-02$15.92/sh−8,080$128,634→ 26,295 total - Sale
Ordinary Shares
2026-01-02$16.70/sh−1,295$21,627→ 25,000 total - Exercise/Conversion
Share Option (right to buy)
2026-01-02−9,375→ 0 totalExercise: $3.14Exp: 2032-01-01→ Ordinary Shares (9,375 underlying)
Footnotes (4)
- [F1]The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
- [F2]These share options are fully vested.
- [F3]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.56 to $16.54 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.61 to $16.79 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Wave Life Sciences Ltd.
CIK 0001631574
Entity typeother
Related Parties
1- filerCIK 0001657709
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 9:30 PM ET
- Size
- 11.0 KB